Analysts Conflicted on These Healthcare Names: BioMarin (SNNA) and Sienna Biopharmaceuticals Inc (SNNA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioMarin (NASDAQ: BMRN) and Sienna Biopharmaceuticals Inc (NASDAQ: SNNA).

BioMarin (NASDAQ: BMRN)

Wedbush analyst Liana Moussatos reiterated a Buy rating on BioMarin (NASDAQ: BMRN) on May 15 and set a price target of $112. The company’s shares closed yesterday at $89.52.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 9.7% and a 44.2% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Catabasis Pharmaceuticals.

Currently, the analyst consensus on BioMarin is Strong Buy and the average price target is $117.31, representing a 31.0% upside.

In a report issued on May 7, Leerink Partners also reiterated a Buy rating on the stock with a $145 price target.

See today’s analyst top recommended stocks >>

Sienna Biopharmaceuticals Inc (NASDAQ: SNNA)

Guggenheim analyst Rohit Vanjani maintained a Hold rating on Sienna Biopharmaceuticals Inc (NASDAQ: SNNA) on May 15. The company’s shares closed yesterday at $14.66, close to its 52-week low of $13.37.

Vanjani wrote:

“We maintain our NEUTRAL rating. 1Q18 Results: LPS for the quarter of ($0.85) was lower than our/consensus estimates of ($0.70)/($0.71) as OpEx of $18.5M was slightly higher than our $17.0M estimate. Cash burn for the quarter was $14.5M. SNNA ended the quarter with $60.0M, which we believe is sufficient to fund operations through 1Q19. Pipeline: SNNA expects top-line results from the pivotal studies for SNA-001 in both acne and the reduction of light-pigmented hair in 2H18. the treatment of psoriasis, SNNA expects phase 1/2 POC results in 3Q18. the treatment of atopic dermatitis, SNNA expects phase 1/2 POC results in 4Q18. the treatment of psoriasis and pruritus associated with psoriasis, the company expects phase 2b top-line results in 1Q19. Model Changes: We are slightly adjusting our estimates to account for the 1Q18 results.”

According to TipRanks.com, Vanjani is a 4-star analyst with an average return of 10.7% and a 50.4% success rate. Vanjani covers the Healthcare sector, focusing on stocks such as Revance Therapeutics, Endo International, and Foamix Pharma.

Sienna Biopharmaceuticals Inc has an analyst consensus of Hold.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.